These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26728187)

  • 1. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
    Ohguchi H; Hideshima T; Bhasin MK; Gorgun GT; Santo L; Cea M; Samur MK; Mimura N; Suzuki R; Tai YT; Carrasco RD; Raje N; Richardson PG; Munshi NC; Harigae H; Sanda T; Sakai J; Anderson KC
    Nat Commun; 2016 Jan; 7():10258. PubMed ID: 26728187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible KDM3A addiction in multiple myeloma.
    Ikeda S; Kitadate A; Abe F; Takahashi N; Tagawa H
    Blood Adv; 2018 Feb; 2(4):323-334. PubMed ID: 29444873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
    Wilson S; Fan L; Sahgal N; Qi J; Filipp FV
    Oncotarget; 2017 May; 8(18):30328-30343. PubMed ID: 28416760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
    Ramadoss S; Guo G; Wang CY
    Oncogene; 2017 Jan; 36(1):47-59. PubMed ID: 27270439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.
    Hou X; Li Q; Yang L; Yang Z; He J; Li Q; Li D
    Exp Biol Med (Maywood); 2021 Sep; 246(17):1869-1883. PubMed ID: 34171978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
    Cho HS; Toyokawa G; Daigo Y; Hayami S; Masuda K; Ikawa N; Yamane Y; Maejima K; Tsunoda T; Field HI; Kelly JD; Neal DE; Ponder BA; Maehara Y; Nakamura Y; Hamamoto R
    Int J Cancer; 2012 Aug; 131(3):E179-89. PubMed ID: 22020899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.
    Pedanou VE; Gobeil S; Tabariès S; Simone TM; Zhu LJ; Siegel PM; Green MR
    Elife; 2016 Jul; 5():. PubMed ID: 27472901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
    Agnarelli A; Chevassut T; Mancini EJ
    Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRF4 addiction in multiple myeloma.
    Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
    Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
    Zhao QY; Lei PJ; Zhang X; Zheng JY; Wang HY; Zhao J; Li YM; Ye M; Li L; Wei G; Wu M
    Clin Epigenetics; 2016; 8():34. PubMed ID: 27034728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
    Sechler M; Parrish JK; Birks DK; Jedlicka P
    Oncogene; 2017 Jul; 36(29):4150-4160. PubMed ID: 28319067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.
    Zhang S; Xu J; Wu S; Wang R; Qu X; Yu W; Li J; Chen L
    Med Oncol; 2013; 30(2):594. PubMed ID: 23666852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
    Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
    Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
    Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
    Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KLF2--a negative regulator of pre-B cell clonal expansion and B cell activation.
    Winkelmann R; Sandrock L; Kirberg J; Jäck HM; Schuh W
    PLoS One; 2014; 9(5):e97953. PubMed ID: 24874925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in osteosarcoma and augment tumor development.
    Wang W; Wang B
    BMC Cancer; 2022 May; 22(1):562. PubMed ID: 35590288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysine-specific demethylase 3A is important for autophagic occurrence.
    Kim J; Choi SA; Kim J; Kim H; Baek SH
    Biochem Biophys Res Commun; 2020 May; 526(1):176-183. PubMed ID: 32201075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
    Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
    Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
    Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
    Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.